Drug Profile
AMT 110
Alternative Names: AMT110; rAAV2/5-hNAGLULatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Amsterdam Molecular Therapeutics
- Developer Institut Pasteur; uniQure
- Class Gene therapies
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III
Most Recent Events
- 27 Nov 2019 UniQure Biopharma completes a phase I/II trial in Mucopolysaccharidosis III (In children) in France (NCT03300453)
- 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Netherlands (Intracerebral)